文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

限制性液体管理对比常规治疗在急性肾损伤中的可行性随机对照试验(REVERSE-AKI)

Restrictive fluid management versus usual care in acute kidney injury (REVERSE-AKI): a pilot randomized controlled feasibility trial.
PubMed 文献 · Intensive Care Med · 2021-05-07
一句话结论在已接受初始液体复苏的急性肾损伤危重患者中,限制性液体管理策略使72小时累积液体平衡更低且不良事件更少。

该多中心可行性随机对照试验在7个欧洲和澳大利亚ICU纳入100例已接受初始液体复苏的急性肾损伤危重患者,1:1随机分为限制性液体管理组和常规治疗组。限制性策略通过减少液体输入和/或由临床医生酌情使用利尿剂增加尿量,以负性或中性每日液体平衡为目标,临床需要时给予液体推注。主要终点72小时累积液体平衡:限制性组-1080 mL(2003 mL)vs常规组61 mL(3131 mL),均值差-1148 mL(95%CI -2200至-96),P=0.033。限制性组接受肾脏替代治疗的比例更低(6/46,13% vs 15/50,30%;RR 0.42,95%CI 0.16-0.91,P=0.043),不良事件更少。作者认为该干预值得开展更大规模试验。

要点

  • 限制性液体管理组72小时累积液体平衡为-1080 mL(2003 mL),常规组为61 mL(3131 mL),均值差-1148 mL(95%CI -2200至-96),P=0.033。
  • 限制性组接受肾脏替代治疗6/46(13%),常规组15/50(30%),风险比RR 0.42(95%CI 0.16-0.91),P=0.043。
  • 急性肾损伤中位持续时间限制性组2[1-3]天,常规组3[2-7]天,中位差-1.0[-3.0至0.0]天,P=0.071。
  • 24小时和7天累积液体平衡在限制性液体管理组均更低。
  • 不良事件在常规治疗组更频繁发生。

适用人群与场景

  • 已接受初始液体复苏的急性肾损伤危重患者,来自欧洲和澳大利亚7个ICU。

处置流程与药物剂量

  • 限制性液体管理:通过减少液体输入和/或由临床医生酌情使用利尿剂增加尿量,以负性或中性每日液体平衡为目标;临床需要时给予液体推注。
  • 利尿剂剂量在两组间无差异。

研究设计与关键结果

  • 多中心可行性随机对照试验,纳入100例急性肾损伤危重患者,1:1随机分为限制性液体管理组和常规治疗组。
  • 主要终点72小时累积液体平衡:限制性组-1080 mL(2003 mL)vs常规组61 mL(3131 mL),均值差-1148 mL(95%CI -2200至-96),P=0.033。
  • 肾脏替代治疗:限制性组6/46(13%)vs常规组15/50(30%),RR 0.42(95%CI 0.16-0.91),P=0.043。
  • 急性肾损伤持续时间中位数:限制性组2[1-3]天 vs常规组3[2-7]天,中位差-1.0[-3.0至0.0]天,P=0.071。
  • 24小时和7天累积液体平衡在限制性液体管理组更低;利尿剂剂量两组无差异;不良事件在常规治疗组更频繁发生。

证据类型、等级与局限

  • 证据类型:多中心可行性随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在急性肾损伤危重患者中,限制性液体管理方案相比常规治疗带来更低的累积液体平衡和更少的不良事件,值得开展更大规模试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: We compared a restrictive fluid management strategy to usual care among critically ill patients with acute kidney injury (AKI) who had received initial fluid resuscitation.

METHODS: This multicenter feasibility trial randomized 100 AKI patients 1:1 in seven ICUs in Europe and Australia. Restrictive fluid management included targeting negative or neutral daily fluid balance by minimizing fluid input and/or enhancing urine output with diuretics administered at the discretion of the clinician. Fluid boluses were administered as clinically indicated. The primary endpoint was cumulative fluid balance 72 h from randomization.

RESULTS: Mean (SD) cumulative fluid balance at 72 h from randomization was - 1080 mL (2003 mL) in the restrictive fluid management arm and 61 mL (3131 mL) in the usual care arm, mean difference (95% CI) - 1148 mL (- 2200 to - 96) mL, P = 0.033. Median [IQR] duration of AKI was 2 [1-3] and 3 [2-7] days, respectively (median difference - 1.0 [- 3.0 to 0.0], P = 0.071). Altogether, 6 out of 46 (13%) patients in the restrictive fluid management arm and 15 out of 50 (30%) in the usual care arm received renal replacement therapy (RR 0.42; 95% CI 0.16-0.91), P = 0.043. Cumulative fluid balance at 24 h and 7 days was lower in the restrictive fluid management arm. The dose of diuretics was not different between the groups. Adverse events occurred more frequently in the usual care arm.

CONCLUSIONS: In critically ill patients with AKI, a restrictive fluid management regimen resulted in lower cumulative fluid balance and less adverse events compared to usual care. Larger trials of this intervention are justified.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Vaara ST, Ostermann M, Bitker L, et al. Restrictive fluid management versus usual care in acute kidney injury (REVERSE-AKI): a pilot randomized controlled feasibility trial. Intensive Care Med. 2021. PMID: 33961058. doi:10.1007/s00134-021-06401-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。